Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel assessment tools to evaluate clinical and laboratory responses in a subset of patients enrolled in the Rituximab in Myositis trial.
Rider LG, Yip AL, Horkayne-Szakaly I, Volochayev R, Shrader JA, Turner ML, Kong HH, Jain MS, Jansen AV, Oddis CV, Fleisher TA, Miller FW. Rider LG, et al. Among authors: volochayev r. Clin Exp Rheumatol. 2014 Sep-Oct;32(5):689-96. Epub 2014 Jul 28. Clin Exp Rheumatol. 2014. PMID: 25068290 Free PMC article. Clinical Trial.
Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.
Pinal-Fernandez I, Pak K, Gil-Vila A, Baucells A, Plotz B, Casal-Dominguez M, Derfoul A, Martinez-Carretero MA, Selva-O'Callaghan A, Sabbagh S, Casciola-Rosen L, Albayda J, Paik J, Tiniakou E, Danoff SK, Lloyd TE, Miller FW, Rider LG, Christopher-Stine L, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Pinal-Fernandez I, et al. Arthritis Rheumatol. 2022 Feb;74(2):358-364. doi: 10.1002/art.41931. Epub 2021 Dec 26. Arthritis Rheumatol. 2022. PMID: 34313394 Free PMC article.
Nodular Regenerative Hyperplasia of the liver in Juvenile Dermatomyositis.
Lanis A, Volochayev R, Kleiner DE, Vittal A, Heller T, Rider LG, Shenoi S. Lanis A, et al. Among authors: volochayev r. Pediatr Rheumatol Online J. 2022 Apr 20;20(1):30. doi: 10.1186/s12969-022-00690-x. Pediatr Rheumatol Online J. 2022. PMID: 35443665 Free PMC article.
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features.
Sherman MA, Graf R, Sabbagh SE, Galindo-Feria AS, Pinal-Fernandez I, Pak K, Kishi T, Flegel WA, Targoff IN, Miller FW, Lundberg IE, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI226-SI234. doi: 10.1093/rheumatology/keac428. Rheumatology (Oxford). 2023. PMID: 35961028 Free PMC article.
Autoantibodies Recognizing Specificity Protein 4 Co-occur With Anti-Transcription Intermediary Factor 1 and Are Associated With Distinct Clinical Features and Immunogenetic Risk Factors in Juvenile Myositis.
Sherman MA, Pak K, Pinal-Fernandez I, Flegel WA, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2023 Sep;75(9):1668-1677. doi: 10.1002/art.42512. Epub 2023 Jul 19. Arthritis Rheumatol. 2023. PMID: 36996276
Clinical Features and Immunogenetic Risk Factors Associated With Additional Autoantibodies in Anti-Transcriptional Intermediary Factor 1γ Juvenile-Onset Dermatomyositis.
Sherman MA, Yang Q, Gutierrez-Alamillo L, Pak K, Flegel WA, Mammen AL, Rider LG, Casciola-Rosen LA; Childhood Myositis Heterogeneity Collaborative Study Group. Sherman MA, et al. Arthritis Rheumatol. 2024 Apr;76(4):631-637. doi: 10.1002/art.42768. Epub 2024 Jan 30. Arthritis Rheumatol. 2024. PMID: 38059274
16 results